QuidelOrtho (NASDAQ:QDEL) Price Target Lowered to $25.00 at JPMorgan Chase & Co.

QuidelOrtho (NASDAQ:QDEL) had its price target reduced by JPMorgan Chase & Co. from $38.00 to $25.00 in a report released on Monday morning,Benzinga reports. They currently have an underweight rating on the stock.

QDEL has been the subject of several other research reports. StockNews.com downgraded shares of QuidelOrtho from a “buy” rating to a “hold” rating in a research report on Saturday, February 15th. Royal Bank of Canada decreased their target price on QuidelOrtho from $64.00 to $61.00 and set an “outperform” rating for the company in a research report on Thursday, February 13th. Finally, UBS Group lifted their price target on QuidelOrtho from $43.00 to $45.00 and gave the company a “neutral” rating in a report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, QuidelOrtho currently has an average rating of “Hold” and an average price target of $46.83.

QuidelOrtho Stock Performance

QDEL opened at $24.56 on Monday. The company has a quick ratio of 0.69, a current ratio of 1.22 and a debt-to-equity ratio of 0.71. The firm has a market cap of $1.66 billion, a PE ratio of -0.81 and a beta of 0.43. The business has a fifty day simple moving average of $34.78 and a 200-day simple moving average of $39.32. QuidelOrtho has a fifty-two week low of $23.77 and a fifty-two week high of $49.45.

QuidelOrtho (NASDAQ:QDEL) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.63 earnings per share for the quarter, missing analysts’ consensus estimates of $1.07 by ($0.44). QuidelOrtho had a negative net margin of 72.84% and a positive return on equity of 3.78%. As a group, equities analysts predict that QuidelOrtho will post 2.3 EPS for the current fiscal year.

Institutional Investors Weigh In On QuidelOrtho

Several large investors have recently made changes to their positions in QDEL. Voya Investment Management LLC raised its position in QuidelOrtho by 7.7% during the fourth quarter. Voya Investment Management LLC now owns 7,551 shares of the company’s stock valued at $336,000 after acquiring an additional 538 shares in the last quarter. Corient Private Wealth LLC raised its holdings in shares of QuidelOrtho by 10.6% during the 4th quarter. Corient Private Wealth LLC now owns 6,874 shares of the company’s stock valued at $306,000 after purchasing an additional 661 shares in the last quarter. Yousif Capital Management LLC lifted its stake in shares of QuidelOrtho by 2.9% in the 1st quarter. Yousif Capital Management LLC now owns 25,950 shares of the company’s stock valued at $907,000 after purchasing an additional 734 shares during the last quarter. Rhumbline Advisers increased its position in QuidelOrtho by 0.6% during the first quarter. Rhumbline Advisers now owns 129,025 shares of the company’s stock worth $4,512,000 after buying an additional 770 shares during the last quarter. Finally, True Wealth Design LLC lifted its position in shares of QuidelOrtho by 300.7% in the fourth quarter. True Wealth Design LLC now owns 1,074 shares of the company’s stock worth $48,000 after buying an additional 806 shares during the last quarter. Institutional investors own 99.00% of the company’s stock.

QuidelOrtho Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.